Clinical drug research in chronic central neurodegenerative disorders

摘要: Several compounds developed the treatment of Alzheimer's disease and Parkinson's have been clinically unsuccessful. Suggested reasons for these failures included heterogeneous symptom expression, inappropriate assessment effects, safety tolerability hurdles, short duration disease-modifying trials, recruiting pressure on study centers, administrative bureaucratic overload, pooling results from trial centers in different health care systems with differing quality therapeutic concepts. The solution to problems will include reducing costs drug development, a concomitant reduction approval hurdles. Trial designs are influenced by ethics committees, officials, political administrations, research scientists. None direct contact treated patients. Approval novel agents lies remit whereby price plays more dominant role than efficacy. Patients prescribing physicians, however, better placed act as arbiters efficacy, risks, overall value new practice.